TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06361810

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administer at 400 mg IV every 6 weeks in combination with 177Lu-PNT2002 until the maximum tolerated dose of 177Lu-PNT2002 is reached during the dose escalation phase.~Pembrolizumab will be administer at 400 mg IV every 6 weeks for a maximum of 17 cycles (6 weeks in each cycle) during the dose expansion phase.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administer at 400 mg IV every 6 weeks in combination with 177Lu-PNT2002 until the maximum tolerated dose of 177Lu-PNT2002 is reached during the dose escalation phase.~Pembrolizumab will be administer at 400 mg IV every 6 weeks for a maximum of 17 cycles (6 weeks in each cycle) during the dose expansion phase.
Study: NCT06251180

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocbrutinib
Description: orally once daily in a 21-day cycle for eight cycles, and as maintenance for 2 years.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocbrutinib
Description: orally once daily in a 21-day cycle for eight cycles, and as maintenance for 2 years.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocbrutinib
Description: orally once daily in a 21-day cycle for eight cycles, and as maintenance for 2 years.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocbrutinib
Description: orally once daily in a 21-day cycle for eight cycles, and as maintenance for 2 years.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m2 administered intravenously once on Day 1 in a 21-day cycle for eight cycles.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m2 administered intravenously once on Day 1 in a 21-day cycle for eight cycles.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m2 administered intravenously once on Day 1 in a 21-day cycle for eight cycles.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m2 administered intravenously once on Day 1 in a 21-day cycle for eight cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 750 mg/m2 administered intravenously once on Day 1 or 2 in a 21-day cycle for six cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 750 mg/m2 administered intravenously once on Day 1 or 2 in a 21-day cycle for six cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 750 mg/m2 administered intravenously once on Day 1 or 2 in a 21-day cycle for six cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 750 mg/m2 administered intravenously once on Day 1 or 2 in a 21-day cycle for six cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin
Description: 50 mg/m2 administered intravenously once on Day 1 or 2 in a 21-day cycle for six cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin
Description: 50 mg/m2 administered intravenously once on Day 1 or 2 in a 21-day cycle for six cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin
Description: 50 mg/m2 administered intravenously once on Day 1 or 2 in a 21-day cycle for six cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin
Description: 50 mg/m2 administered intravenously once on Day 1 or 2 in a 21-day cycle for six cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristin
Description: 1.4 mg/m2 administered intravenously once on Day 1 or 2 in a 21-day cycle for six cycles.
Study: NCT05573009

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive behavioral approach-based stress reduction program
Description: Five days lasting stress reduction program based on cognitive behavioral approach(each session will be an average of 60 minutes) will be initiated in the third day of hospitalisation to the intervention group.~Session main topics are:~Session 1 - Introducing the purpose and content of the program - Stress Psychoeducation Session 2 - Cognitive restructuring Session 3 -Behavioral coping Session 4 - Problem solving training Session 5-Upcoming parenthood
Study: NCT05449353

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trauma-informed Cognitive Behaviour Therapy (TiCBT)
Description: Group: Experimental (n=24 participants) will receive the TiCBT which consists of a total of 8-group integrated sessions lasting approximately 60 minutes per session every 3 days interval with 24 persons in the single group.
Study: NCT06512987

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: technology-driven, interactive ICU diary
Description: Through the diary platform, patients can share their feelings and needs, while family members can send supportive messages, pictures, and videos. Healthcare providers will use the platform to connect with families and monitor patient conditions.
Study: NCT06511414

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: duramesh
Description: Duramesh™ non-absorbable polypropylene suture is a hollow core, microporous, cylindrical suture made off in polypropylene filaments that are loosely braided and bonded to each other with heat and pressure

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: standard closure of fascia
Study: NCT06251180

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristin
Description: 1.4 mg/m2 administered intravenously once on Day 1 or 2 in a 21-day cycle for six cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristin
Description: 1.4 mg/m2 administered intravenously once on Day 1 or 2 in a 21-day cycle for six cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristin
Description: 1.4 mg/m2 administered intravenously once on Day 1 or 2 in a 21-day cycle for six cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 100 mg orally once on Day 1 to Day 5 in a 21-day cycle for six cycles.
Study: NCT05458622

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Saliva sample
Description: - Saliva: will be collect in special container for saliva microbiome and methylation;

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Stood sample
Description: - Stool: One sample for microbiome to be sent to the biobank, frozen at -80 °C

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Tissue sample
Description: - Tissue samples for organ-specific manifestations:~* Kidney tissue in lupus nephritis: one small fragment of the fresh kidney biopsy will be stored in a 10% dimethyl sulfoxide (DMSO) solution (slow freezing to -80 °C) until shipment.~* Skin tissue (at selected centers) from inflamed lesion and non-inflamed skin from the gluteal region will be obtained through punch biopsy and stored in a 10% dimethyl sulfoxide (DMSO) solution (slow freezing to -80 °C) until shipment.~* Synovial tissue (at selected centers) will be obtained through ultrasound-directed arthroscopy and stored in a 10% dimethyl sulfoxide (DMSO) solution (slow freezing to -80 °C) until shipment.~* Aspirate from swollen lymph nodes (at selected centers) will be obtained and stored in a 10% dimethyl sulfoxide (DMSO) solution (slow freezing to -80 °C) until shipment.
Study: NCT05660135

Intervention type: DRUG
Intervention: Olmesartan Medoxomil/ Amlodipine Besylate/ Rosuvastatin Ca
Description: Olomax Tab 20/5/5mg Olomax Tab 20/5/10mg Olomax Tab 40/5/5mg Olomax Tab 40/5/10mg
Study: NCT06537310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7567132 and Atezolizumab
Description: RO7567132 will be administered either as monotherapy or in combination with atezolizumab at a dose and schedule as specified for the respective cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7567132 and Atezolizumab
Description: RO7567132 will be administered in combination with atezolizumab at a dose and schedule as specified for the respective cohort.
Study: NCT06251180

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 100 mg orally once on Day 1 to Day 5 in a 21-day cycle for six cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 100 mg orally once on Day 1 to Day 5 in a 21-day cycle for six cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 100 mg orally once on Day 1 to Day 5 in a 21-day cycle for six cycles.
Study: NCT06122051

Intervention type: RADIATION
Intervention: Dynamic chest x-ray
Description: Group A and Group B- posterior-anterior dynamic chest x-ray film (Group A, This will represent an additional intervention not part of standard clinical care) (Group B, People with CF, already have this as part of their annual review process)

Intervention type: RADIATION
Intervention: Dynamic chest x-ray
Description: Group A and Group B- posterior-anterior dynamic chest x-ray film (Group A, This will represent an additional intervention not part of standard clinical care) (Group B, People with CF, already have this as part of their annual review process)

Intervention type: DIAGNOSTIC_TEST
Intervention: Spirometry
Description: Group A and Group B- Spirometry lung function test (Group A, This will represent an additional intervention not part of standard clinical care) (Group B, People with CF, already have this as part of their annual review process)

Intervention type: DIAGNOSTIC_TEST
Intervention: Spirometry
Description: Group A and Group B- Spirometry lung function test (Group A, This will represent an additional intervention not part of standard clinical care) (Group B, People with CF, already have this as part of their annual review process)
Study: NCT04983498

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron 4 MG
Description: PONV prophylaxis for participants with an apfel score of 2 or greater (ondansetron 4 mg IV), an additional dose of ondansetron 4mg IV will be available in recovery if the patient has nausea/vomiting despite prophylaxis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactated Ringers, Intravenous
Description: Goal directed IV fluids to be administered starting preop per the NMH Colorectal ERAS protocol (LR @ 5mL/kg/hr).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early Mobilization
Description: Patient transferred up to the chair (within 5-30 minutes of admission to the recovery room) based on nursing parameters and patient safety.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early PO Intake
Description: Patient will be offered PO intake within 15-30 minutes of admission to the recovery room post-procedure based on nursing parameters and patient safety.
Study: NCT04874441

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Diagnosis strategy based on C. glabrata / krusei PCR
Description: For diagnosis, a blood cultures and blood tubes for PCR will be collected and patients will be treated with echinocandins in the first instance with an early switch to fluconazole if the C. glabrata / krusei PCR is negative
Study: NCT05161156

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Test Product (tiotropium bromide inhalation powder)
Description: A single dose of test product

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: 18 mcg of Spiriva (Reference Product)
Description: A single dose of reference product (Spiriva)

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: A single dose of placebo

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: A single dose of placebo

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A single dose of placebo
Study: NCT05105607

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-4517.2
Description: Subcutaneous (SC) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-4517.2
Description: Subcutaneous (SC) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-4517.2
Description: Subcutaneous (SC) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-4517.2
Description: Subcutaneous (SC) injection
Study: NCT04942496

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine Gluconate
Description: Antimicrobial Skin Wash

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine Gluconate
Description: Antimicrobial Skin Wash

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine Gluconate
Description: Antimicrobial Skin Wash

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine Gluconate
Description: Antimicrobial Skin Wash

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine Gluconate
Description: Antimicrobial Skin Wash

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine Gluconate
Description: Antimicrobial Skin Wash

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine Gluconate
Description: Antimicrobial Skin Wash

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine Gluconate
Description: Antimicrobial Skin Wash

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine Gluconate
Description: Antimicrobial Skin Wash

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hibi Universal Bathing System
Description: Cloths used for patient bathing

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 0.1% SLS
Description: Positive control

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Distilled Water
Description: Negative Control
Study: NCT04599335

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 2% HA
Description: 2% HA
Study: NCT05070338

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guideline-Based (Injunctive Norm) Nudges
Description: Surgeons in this arm will receive an email with the following content at the end of each month in which at least two of their patients are discharged with an opioid prescription that exceeds the prescribing guideline for the procedure performed.~Dear Dr. \[Name\],~In \[month\], at least XX of your patients were discharged with opioid prescriptions exceeding the amounts recommended by safety guidelines for these procedures.~For patient safety, Sutter Health recommends prescribing within the ranges below for these procedures. Doing so will also meet best-practice safety guidelines for post-operative opioid prescribing.~We will continue to send you opioid prescribing safety reports.~Sincerely, \[Signature\]~\[Table displaying recommended ranges of 5mg oxycodone tablets for each procedure\]

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer-Based (Social Norm) Nudges
Description: Surgeons in this arm will receive an email with the following content at the end of each month in which at least two of their patients are discharged with an opioid prescription that exceeds the prescribing guideline for the procedure performed.~Dear Dr. \[Name\],~In \[month\], at least XX of your patients were discharged with opioid prescriptions exceeding the amount prescribed by YY% of your peers for these procedures.~YY% of \[specialty\] surgeons at Sutter Health prescribe within the ranges below for these procedures.~We will continue to send you opioid prescribing safety reports.~Sincerely, \[Signature\]~\[Table displaying recommended ranges of 5mg oxycodone tablets for each procedure\]~The ranges of 5mg oxycodone tablets displayed will be the same as the ranges stipulated by the prescribing guidelines, but this nudge will not mention guidelines.
Study: NCT04885010

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: probiotics
Description: participants will be given probiotics twice a day for 15 days

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: participants will be given a placebo twice a day for 15 days
Study: NCT04741256

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education booklet & standardized discharge training
Description: Tracheostomy education booklet and tracheostomy teaching performed by nurses during hospitalization as dictated by the booklet.
Study: NCT06213805

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Minimally invasive microsclerostomy
Description: MIMS is a filtering glaucoma surgery, which consists of creating a sclero-corneal drainage channel, to allow the flow of aqueous humor and therefore the reduction of intraocular pressure.~This surgery is extremely quick, lasting 3 to 5 minutes, according to recent MIMS studies, in contrast to the duration of a trabeculectomy, the classic glaucoma surgery, which varies between 20 and 60 minutes.
Study: NCT06673212

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Wheat Bread
Description: Ingredients: Wheat Flour, Salt, Water, Allinson's Dried Active Yeast, Sugar

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Berneray Bere barley bread
Description: Ingredients: Berneray Bere Barley Flour, Salt, Water, Allinson's Dried Active Yeast, Sugar

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Black Barley bread
Description: Ingredients: Black Barley Flour, Salt, Water, Allinson's Dried Active Yeast, Sugar
Study: NCT03999216

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Loop Diuretics vs. loop + thiazide diuretics
Description: Participants will receive the diuretic type as determined by the randomized group assignment starting within the first 24 hours of hospital admission and continuing for up to 72 hours. All other treatments are left to the discretion of the treatment team, as this is a pragmatic randomized trial.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Loop Diuretics vs. loop + thiazide diuretics
Description: Participants will receive the diuretic type as determined by the randomized group assignment starting within the first 24 hours of hospital admission and continuing for up to 72 hours. All other treatments are left to the discretion of the treatment team, as this is a pragmatic randomized trial.
Study: NCT05454683

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: melatonin plus zinc
Description: One capsule with melatonin 1mg plus zinc 10 mg o.d. 30 minutes before bedtime, at least 1 hour after dinner during 4 months

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: isomaltose and magnesium stearate
Description: One capsule with excipients o.d. 30 minutes before bedtime, at least 1 hour after dinner during 4 months
Study: NCT04972760

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Baricitinib, 4 mg/d, oral route for 24 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, 4 mg/d, oral route for 24 weeks
Study: NCT05475678

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: （Carrelizumab + TCb） regimen
Description: Carrelizumab +docetaxel + carboplatin regimen

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TCb regimen
Description: docetaxel + carboplatin regimen
Study: NCT06665555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ledaborbactam etzadroxil
Description: Five doses of ledaborbactam etzadroxil will be administered orally every 12 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ceftibuten
Description: Five doses of ceftibuten will be administered orally every 12 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ceftibuten
Description: Five doses of ceftibuten will be administered orally every 12 hours
Study: NCT06665802

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Questionnaire completion

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Questionnaire completion
Study: NCT06667622

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium glycididazole
Description: Sodium glycididazole is intravenously infused at a dose of 800mg at 60 min before radiotherapy and used on Mondays, Wednesdays and Fridays during radiotherapy.
Study: NCT06666725

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Menu label
Description: Participants will select food items from three restaurant menus, displayed with labels as specified by their assigned group
Study: NCT06232031

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active Breathing Exercises
Description: Active breathing exercises aim to enhance the strength and flexibility of respiratory muscles through a series of exercises, improving breathing patterns and increasing respiratory efficiency. The following are common components of active breathing exercises: 1) Deep Breathing. 2) Chest Expansion. 3) Diaphragmatic Breathing. 4) Coughing Techniques. 5) Expiratory Resistance Training. 6) Gradual Increase in Activity.
Study: NCT06057428

Intervention type: PROCEDURE
Intervention: Decompressive surgery
Description: Decompressive surgery for lumbar spinal stenosis
Study: NCT05756309

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrocardiogram measurements by holter device and patch-type electrocardiographic at the same time
Description: The patient is measured electrocardiogram simultaneously through a holter device and patch-type electrocardiograph
Study: NCT06544395

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non invasive neuromodulation therapy
Description: In the 4 studies, the intervention consisted of 15 sessions spread over 5 weeks.~Each intervention lasted 60 minutes. The intensity will be programmed in all sessions at Low, following the Arndt-Schulz law. The treatment was distributed in 3 phases: phase 1 of preparation, phase 2 to reduce fatigue and phase 3 to enhance autonomic improvement.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual therapy
Description: Common manual therapy administered for said pathology by traditional physiotherapy and therapeutic exercise.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo with non invasive neuromodulation
Description: In the 4 studies, the intervention consisted of 15 sessions spread over 5 weeks.~Each intervention lasted 60 minutes. The treatment was carried out with the machine turned off.
Study: NCT05697003

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 1000 mcg and salmeterol xinafoate 50 mcg/Respirent Pharmaceuticals
Description: 2 inhalations in one study period

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ADVAIR DISKUS 100/50
Description: 2 inhalations in one study period
Study: NCT06386120

Intervention type: OTHER
Intervention: PEEP setting strategy
Description: The attending physician selects different PEEP setting strategies

Intervention type: OTHER
Intervention: PEEP setting strategy
Description: The attending physician selects different PEEP setting strategies
Study: NCT05648916

Intervention type: OTHER
Intervention: Celecoxib
Description: Retrospectively comparing patients with and without heterotopic ossification who have been exposed to celecoxib and underwent cementless total hip joint replacement surgery.
Study: NCT06182722

Intervention type: DIAGNOSTIC_TEST
Intervention: Mental assessments
Description: Patients will receive psychiatric rating scales evaluation every visit.